Cargando…

Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: Short-term results

AIMS: To compare the short-term therapeutic effects of intravitreal bevacizumab (IVB) to those of photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV). MATERIALS AND METHODS: Retrospective interventional case study. Eighty-nine eyes of 89 patients with symptomatic PCV were treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitamura, Yoshinori, Kitahashi, Masayasu, Kubota-Taniai, Mariko, Yamamoto, Shuichi
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907029/ https://www.ncbi.nlm.nih.gov/pubmed/20534918 http://dx.doi.org/10.4103/0301-4738.64130

Ejemplares similares

Pneumatic displacement with intravitreal bevacizumab for massive submacular hemorrhage due to polypoidal choroidal vasculopathy
por: Kitahashi, Masayasu, et al.
Publicado: (2014)

One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy
por: Sakurai, Madoka, et al.
Publicado: (2014)

Treatment of polypoidal choroidal vasculopathy with intravitreal bevacizumab monotherapy
por: Tan, Colin S H, et al.
Publicado: (2013)

Intravitreal bevacizumab monotherapy for treatment-naive polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar, et al.
Publicado: (2014)

Intravitreal bevacizumab monotherapy for treatment-naïve polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar, et al.
Publicado: (2013)

Short-term Effectiveness of Intravitreal Bevacizumab vs. Ranibizumab Injections for Patients with Polypoidal Choroidal Vasculopathy
por: Cho, Han Joo, et al.
Publicado: (2012)

Changes in visual function and thickness of macula after photodynamic therapy for age-related macular degeneration
por: Okada, Kyoko, et al.
Publicado: (2009)

Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choroidal osteoma
por: Kubota-Taniai, Mariko, et al.
Publicado: (2011)

Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: one-year follow-up
por: Romano, Mario R, et al.
Publicado: (2010)

Authors’ reply
por: Mitamura, Yoshinori, et al.
Publicado: (2010)

Intravitreal bevacizumab associated with photodynamic therapy in a case of polypoidal choroidal vasculopathy associated with choroidal nevus: A case report
por: Rangel, Carlos M., et al.
Publicado: (2017)

Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
por: Singh, Sumit Randhir, et al.
Publicado: (2019)

Disadvantages of photodynamic therapy for polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar
Publicado: (2010)

Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy
por: Peng, Yuting, et al.
Publicado: (2018)

Short-Term Efficacy in Polypoidal Choroidal Vasculopathy Patients Treated With Intravitreal Aflibercept or Conbercept
por: Xue, Yin, et al.
Publicado: (2022)

Photodynamic therapy for polypoidal choroidal vasculopathy secondary to choroidal nevus
por: Wong, James G, et al.
Publicado: (2017)

Subretinal Hemorrhage after Photodynamic Therapy for Juxtapapillary Retinal Capillary Hemangioma
por: Baba, Takayuki, et al.
Publicado: (2011)

Long-Term Effects of Half-Time Photodynamic Therapy on Retinal Sensitivity in Eyes with Chronic Central Serous Chorioretinopathy
por: Iwase, Takehito, et al.
Publicado: (2020)

The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal Vasculopathy
por: Lee, Sun Young, et al.
Publicado: (2008)

One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
por: Weng, Hsin-Yu, et al.
Publicado: (2019)

Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup
por: Fernández, Maribel, et al.
Publicado: (2012)

Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy
por: Azuma, Keiko, et al.
Publicado: (2020)

Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
por: Sonoda, Shozo, et al.
Publicado: (2013)

Management of peripheral polypoidal choroidal vasculopathy with intravitreal bevacizumab and indocyanine green angiography-guided laser photocoagulation
por: Rishi, Pukhraj, et al.
Publicado: (2012)

Practicability confirmation by meta-analysis of intravitreal ranibizumab compared to photodynamic therapy to treat polypoidal choroidal vasculopathy
por: Liu, Ling, et al.
Publicado: (2015)

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Wataru, Kikushima, et al.
Publicado: (2020)

Long-Term Prognosis of Patients with Polypoidal Choroidal Vasculopathy Treated with Photodynamic Therapy
por: Sakaeda, Yukinori, et al.
Publicado: (2023)

Author reply to comment on photodynamic therapy and polypoidal choroidal vasculopathy
por: Williams, Gwyn Samuel, et al.
Publicado: (2014)

Choroidal structure as a biomarker for visual acuity in intravitreal aflibercept therapy for polypoidal choroidal vasculopathy
por: Asano, Shotaro, et al.
Publicado: (2018)

Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
por: Lai, Kunbei, et al.
Publicado: (2018)

Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2020)

Visual Parameters and Retinal Morphology for Polypoidal Choroidal Vasculopathy Pre- and Post-Intravitreal Ranibizumab with or without Photodynamic Therapy: A Short-Term Prospective Study
por: Ghoshal, Rituparna, et al.
Publicado: (2021)

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013)

Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
por: Lee, Sang Eun, et al.
Publicado: (2019)

Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy
por: Arakawa, Akira, et al.
Publicado: (2017)

Polypoidal choroidal vasculopathy—characteristics and response to treatment with bevacizumab in caucasian patients
por: Zhalka, Fidaa El, et al.
Publicado: (2022)

Polypoidal Choroidal Vasculopathy in Asians
por: Wong, Chee Wai, et al.
Publicado: (2015)

Clinical implications of pachyvessels in polypoidal choroidal vasculopathy
por: Ijuin, Nobuo, et al.
Publicado: (2020)

Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
por: Yamashita, Mariko, et al.
Publicado: (2014)

Ethnic differences on long term outcomes of polypoidal choroidal vasculopathy after predominantly bevacizumab monotherapy
por: Yap, Aaron, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_favth86jk9bpdfvbu8bfmo7ha1